{"id":"W4417114937","doi":"10.1111/all.70181","title":"Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria","year":2025,"lang":"en","type":"article","venue":"Allergy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novartis Pharma; Genentech; National Institutes of Health; Eisai; Mitsubishi Tanabe Pharma Corporation; Celltrion; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Galderma; Eli Lilly and Company; AstraZeneca; CSL Behring; Aimmune Therapeutics; Taiho Pharmaceutical; LEO Pharma; BioMarin Pharmaceutical; Kaken Pharmaceutical; Sanofi; Amgen; Kyorin Pharmaceutical; Pfizer","keywords":"Immunopathology; MEDLINE; Chronic urticaria; Autoimmune disease; Angioedema; Allergy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00001766033,0.0001171735,0.0002364558,0.0001139511,0.00003887451,0.000005158583,0.00003791754,0.00009429827,0.0001745908],"category_scores_gemma":[0.00001952059,0.00008296886,0.00003150261,0.0001640563,0.00007976153,0.00002164456,0.00002389622,0.00009396432,0.000009534435],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001970679,"about_ca_system_score_gemma":0.000227793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001774548,"about_ca_topic_score_gemma":0.0004828379,"domain_scores_codex":[0.99929,0.00002172623,0.0002170806,0.0001932288,0.0001087034,0.0001692344],"domain_scores_gemma":[0.9995351,0.00006614552,0.00003650462,0.0002433018,0.00004812283,0.00007076961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03816069,0.01489608,0.733885,0.0002735236,0.03127049,0.007883298,0.00514422,0.0006313586,0.002501156,0.03466041,0.0007807261,0.129913],"study_design_scores_gemma":[0.01276055,0.002346697,0.9826193,0.0003486035,0.0006570767,0.00005122936,0.00001504442,0.00003109021,0.0002742752,0.00007104855,0.0007364299,0.00008858366],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912624,0.0005756737,0.00001522029,0.0005867363,0.00006416402,0.0004481418,0.000005578792,0.00002111482,0.007020998],"genre_scores_gemma":[0.9982851,0.000409577,0.00004036465,0.00006647313,0.00001475956,0.00001534529,0.00007199397,0.00001033884,0.001086091],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2487343,"threshold_uncertainty_score":0.3383372,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00447194017327993,"score_gpt":0.2335508368203654,"score_spread":0.2290788966470854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}